Quadrature Capital LTD Lineage Cell Therapeutics, Inc. Transaction History
Quadrature Capital LTD
- $8.45 Trillion
- Q3 2025
A detailed history of Quadrature Capital LTD transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Quadrature Capital LTD holds 179,031 shares of LCTX stock, worth $340,158. This represents 0.0% of its overall portfolio holdings.
Number of Shares
179,031Holding current value
$340,158% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
128Shares Held
96MCall Options Held
251KPut Options Held
50K-
Broadwood Capital Inc New York, NY49.6MShares$94.2 Million5.18% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$18.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.01MShares$17.1 Million0.0% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$10.2 Million10.91% of portfolio
-
Comerica Bank4.6MShares$8.74 Million0.03% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $323M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...